Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
WST · NYSE · Healthcare
Fundamental quality
78
out of 100
West Pharmaceutical Services Inc fits the profile of a quality compounder: it pairs high return on capital (ROE 18.9%) with wide margins (net margin 17%) and a business that keeps growing (8.3% a year). On fundamental quality it scores 78 out of 100, profiling it as a company with solid fundamentals. Its weakest area is its growth (revenue +8.3%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
West Pharmaceutical makes the components that seal injectable drugs: stoppers, plungers and delivery systems found in the vast majority of the world's biologic medicines. A business tiny in appearance and critical in practice: without its rubber, insulin doesn't travel.
EPS growth: 10.2% · Revenue growth: 8.3%
Net margin: 17% · ROE: 18.9% · ROIC: 19.5%
Net debt/EBITDA: -0.27x · FCF: 13.1%
Source: SEC EDGAR · TTM through 30/06/2026
The score includes +4 for dividend strength: 33 consecutive years of increases. Keeping that streak demands growing cash generation and balance-sheet discipline.
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 2,147 | 346 | 298 | -360 |
| 2021 | 2,832 | 662 | 331 | -510 |
| 2022 | 2,887 | 586 | 439 | -685 |
| 2023 | 2,950 | 593 | 415 | -647 |
| 2024 | 2,893 | 493 | 276 | -282 |
| 2025 | 3,074 | 494 | 469 | -588 |
Between 2020 and 2025, revenue went from $2,147M to $3,074M (+43%) and net income went from $346M to $494M (+43%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$0.86
per share, yearly
12.4% of earnings
Payout
33 straight years raising it
Growth
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is West Pharmaceutical Services Inc cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is West Pharmaceutical Services Inc a good company to invest in?
In terms of business quality, West Pharmaceutical Services Inc scores 78 out of 100 in our analysis, placing it as a company of high fundamental quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is West Pharmaceutical Services Inc a profitable company?
Yes. West Pharmaceutical Services Inc shows a net margin of 17% and an ROE of 18.9%, a sign of a profitable business.
Does West Pharmaceutical Services Inc have a lot of debt?
No. West Pharmaceutical Services Inc has a net cash position: more cash than debt.
Is West Pharmaceutical Services Inc growing?
Its revenue has grown 8.3% annualized in recent years and its earnings per share 10.2%.
Does West Pharmaceutical Services Inc generate cash?
Yes. It converts about 13.1% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Elevance Health (ELV) · McKesson (MCK) · Zoetis (ZTS) · CVS Health (CVS) · 3M (MMM) · HCA Healthcare (HCA) · see more →
The best Healthcare stocks by our model →
Compare West Pharmaceutical Services Inc with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see West Pharmaceutical Services Inc's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.